Can Fite Biopharma Ltd (NASDAQ:CANF) received a $7.00 target price from equities researchers at Maxim Group in a research report issued on Tuesday, October 17th. The firm currently has a “buy” rating on the stock. Maxim Group’s price objective would indicate a potential upside of 360.53% from the company’s previous close.
Separately, HC Wainwright set a $6.00 price target on Can Fite Biopharma and gave the company a “buy” rating in a report on Thursday, August 10th.
Can Fite Biopharma (CANF) traded down $0.03 on Tuesday, reaching $1.52. The company’s stock had a trading volume of 30,487 shares, compared to its average volume of 24,977. Can Fite Biopharma has a one year low of $1.50 and a one year high of $2.67.
Can Fite Biopharma Company Profile
Can Fite Biofarma Ltd is an Israel-based biopharmaceutical company. The Company develops new treatments for autoimmune diseases and cancer. The Company’s drugs are CF101 for Psoriasis treatment, RA treatment, for the treatment of Keratoconjunctictivitis Sicca, for the treatment of Glaucoma, among others; and CF102 for the treatment of liver diseases.
Receive News & Ratings for Can Fite Biopharma Ltd Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Can Fite Biopharma Ltd and related companies with our FREE daily email newsletter.